Articles tagged with Lung Cancer
A study of nearly 100 studies supports thermal ablation as a successful alternative to surgery and radiation therapy for patients with advanced lung cancer. The procedure has achieved an overall survival rate of 48-80 percent at two years, offering a safe and effective treatment option.
Researchers found that smokers who light up within 30 minutes of waking have a higher risk of developing lung and head and neck cancers. This increased risk is independent of smoking frequency and duration, suggesting that nicotine dependence may play a role in cancer development.
Researchers have found that sniffer dogs can reliably detect lung cancer by identifying volatile organic compounds in patients' breath. The study, published in the European Respiratory Journal, used trained dogs to detect lung cancer with an accuracy rate of 71%, surpassing current detection methods.
A CAMH study found that a specific gene combination significantly increases lung cancer risk, particularly among light smokers with two high-risk variants of the nicotine metabolic and nicotinic genes. The genetic risk was higher in lighter smokers, suggesting a need for targeted interventions to reduce lung cancer risk.
Smokers who light up within 30 minutes of waking are 1.79 times more likely to develop lung cancer and 1.59 times more likely to develop head and neck cancer compared to those who delay smoking for over an hour. Targeted smoking cessation programs may help reduce tobacco's negative health effects.
A new study published in The Lancet found that platinum-based doublet chemotherapy is associated with improved survival rates for elderly patients with non-small-cell lung cancer. The treatment showed better results compared to monotherapy in patients over 70 years old, suggesting a potential shift in the current treatment strategy for...
A new, cost-effective method for detecting ALK rearrangement in non-small cell lung cancer patients has been developed. This approach is comparable to the established gold standard, fluorescence in situ hybridization (FISH), and could enable more patients to access potentially life-saving crizotinib therapy.
The OPTIMAL trial found erlotinib significantly prolonged median progression-free survival compared to chemotherapy (13.1 months vs 4.6 months). Serious treatment-related side effects were also more common in patients receiving chemotherapy.
Researchers have identified a way to exploit brain's self-repair mechanism to protect nerve cells and enhance brain repair after stroke. Estradiol has been shown to protect male rats against beta-cell failure in rodent models of type 2 diabetes, suggesting estrogen receptors as a viable therapeutic target.
Research suggests that adding an inferior vena cava filter (IVCF) to the anticoagulant medication fondaparinux does not improve treatment outcomes for cancer patients with blood clots. In fact, median survival was shorter and VTE resolution rates were lower in patients who received both treatments.
A new study published in the Journal of Thoracic Oncology found that endosonography followed by surgical staging significantly improved the quality of life for lung cancer patients. The study, which compared two strategies for mediastinal staging, showed no significant difference in costs between the two approaches.
The TEMLA procedure demonstrated a higher diagnostic yield than EBUS and EUS in detecting cancer in primary staging, with a sensitivity of 98.6% compared to 88.9% for EBUS/EUS. Additionally, TEMLA showed superior performance in restaging procedures, with a sensitivity of 95.5% and specificity of 100%.
The Cancer Risk Management model uses dynamic simulations to project realistic Canadian populations, offering insights into screening, prevention, and treatment changes. By reducing smoking rates, the model predicts a decrease in lung cancer incidence and cumulative savings in direct treatment costs.
Research reveals disparities in trial populations reflecting U.S. demographics, with women and older patients under-enrolled. Minority groups also show significant underrepresentation, highlighting concerns about toxicity and treatment efficacy.
Researchers sequenced a patient's entire DNA and RNA to identify the origins of their metastatic adenocarcinoma of the lung, a mutation in the TP53 gene being found to halt tumor suppressor gene creation and result in tumor generation
The study found that trusts with more pure thoracic surgeons saw a significant increase in lung cancer resection rates. In 2009, the overall resection rate rose by 46% due to increased investment in thoracic surgical expertise.
New treatment options, including stereotactic ablative radiotherapy, have led to significant improvements in the survival of elderly Dutch lung cancer patients. Median survival for NSCLC patients increased by nearly 8 months between 2003 and 2009.
A recent study found that celecoxib reduced the Ki-67 labeling index by 34% in former smokers, indicating a potential chemopreventive effect against lung cancer. The medication was also linked to a reduction in lung nodules, a precursor to cancer.
A new study reveals that ALK rearrangement affects nearly 10% of lung cancer patients, while MET amplification occurs in another 4.1%. This could lead to targeted therapy options like crizotinib for these patients.
A new PET imaging technique using [11C]erlotinib may help doctors identify lung cancers that respond well to tyrosine kinase inhibitors (TKIs), enabling personalized therapy. The test showed significantly higher tracer uptake in tumors with activating EGFR mutations, indicating a potential non-invasive predictive marker.
The EURTAC Phase III study found that erlotinib nearly doubled progression-free survival compared to chemotherapy, with a better tolerability profile for Western patients with NSCLC and EGFR activating mutations. The response rate to erlotinib was 54.5%, significantly higher than the 10.5% response rate to chemotherapy.
Research reveals that lung adenocarcinomas in never-smokers exhibit greater genome instability and altered genetic patterns compared to those in smokers. The findings suggest distinct molecular mechanisms driving the development of lung cancer in never-smokers, potentially requiring unique treatments.
Research found that high EGFR expression is a predictor of improved survival in advanced non-small cell lung cancer patients treated with cetuximab and chemotherapy. Patients with high tumor EGFR expression averaged 12 months of overall survival, compared to 9.6 months for those without high expression.
The LuCED test uses 3D imaging to accurately detect cancer cells in sputum samples from high-risk individuals. This approach can significantly lower the number of false positive cases, making mass screening programs more feasible and cost-effective.
A study published in the New England Journal of Medicine confirms that helical low-dose CT scans for lung cancer reduce deaths in heavy smokers by 20 percent. The research also highlights the need for further analysis on cost-effectiveness, downstream consequences, and screening strategies.
The University of Texas M.D. Anderson Cancer Center has introduced a comprehensive lung cancer screening program to detect the disease early. With computed tomography (CT) scans, the program reduces lung cancer-specific mortality by 20%, improving health outcomes for high-risk individuals.
The International Association for the Study of Lung Cancer (IASLC) welcomed the publication of positive results from the National Lung Screening Trial, which showed a 20% reduction in lung cancer deaths and a 7% decrease in all-cause mortality among heavy smokers screened with low-dose spiral computed tomography. The trial followed ove...
A new study published in New England Journal of Medicine found that CT scans can detect lung cancer at an early stage, reducing death rates by 20%. The trial involved over 53,000 current or former heavy smokers and showed improved survival rates for those who received the CT scan.
The study found a significant reduction in lung cancer deaths among heavy smokers screened with low-dose helical CT, with a 20% decrease compared to those screened with chest X-ray. The screening test identified adenocarcinomas and squamous cell carcinomas at early stages of disease, providing valuable insights for future patients.
The National Lung Screening Trial (NLST) found that low-dose helical computed tomography (CT) screening reduced lung cancer deaths among participants who were screened with CT versus those screened with chest X-ray. The study enrolled 53,000 current and former heavy smokers aged 55 to 74.
A large clinical trial found that low-dose spiral CT scanning reduced lung cancer deaths by 20% compared to chest X-ray screening. The study involved over 53,000 participants and provided conclusive evidence of the mortality benefit from CT screening.
The American Cancer Society's latest report finds a steady decline in overall cancer death rates since the early 1990s, with about 898,000 deaths avoided between 1990 and 2007. However, progress has not benefited all segments of the population equally, with cancer death rates among less-educated individuals being more than twice those ...
A gene linked to emphysema is also found to contribute to lung cancer development, with men showing a higher incidence of the disease. The study suggests that PLAGL2 expression could be used as a marker for cells at risk of malignant transformation.
A clinical trial revealed crizotinib's effectiveness in shrinking tumors and improving responses in over 60% of ALK-positive advanced non-small cell lung cancer patients. The treatment has shown dramatic benefits with minimal side effects, opening new avenues for targeted therapy.
Scientists have identified a drug combination that shows a survival advantage in advanced lung cancer patients who no longer respond to existing therapies. The combination of bexarotene and erlotinib broadens the reach to include patients resistant due to ras mutations, offering new hope for those with limited treatment options.
Researchers found Asian non-small cell lung cancer patients survived longer than Caucasians regardless of the number of chemotherapy drugs given, with improved survival rates after targeted therapies were introduced in the early 2000s.
Five advocacy organizations from India, Australia and the US have been granted travel awards by IASLC to attend the 14th World Conference on Lung Cancer in Amsterdam. The winners will enjoy free registration, accommodation and travel expenses, as well as free IASLC affiliate membership.
End-of-life care for cancer patients varies significantly between the US and Canada, with higher rates of hospital admissions and emergency room visits in Ontario compared to the US. In contrast, US patients receive more chemotherapy, particularly in the last month of life.
Scientists have identified key molecular patterns in the blood of lung cancer patients, which can help detect the disease at an early stage. The study found these patterns are present even in tumors still in their earliest stages, offering new hope for improving lung cancer diagnosis and treatment.
A study suggests that evaluating gene expression changes in nasal cells can serve as a non-invasive approach for early detection of lung cancer. The researchers identified 170 genes that were differentially expressed between patients with and without lung cancer, including genes linked to colon cancer and tumor suppression.
Research by Dr. Inés Ibañez-Tallon and her team at MDC Berlin-Buch reveals that the midbrain habenula region plays a key role in nicotine dependence. The study found that only a balanced activity of two genes can rein in nicotine use.
Researchers identified characteristic patterns of molecules called microRNA (miRNA) in the blood of people with lung cancer that may reveal its presence and aggressiveness. These patterns could potentially lead to a blood test for early detection, even up to two years before tumor formation.
A study published in the Journal of the National Cancer Institute found that patient reports of family cancer history are not highly accurate. The study revealed low to moderate accuracy rates for breast, colorectal, prostate, and lung cancer diagnoses, with higher accuracy rates for first-degree relatives
UCLA researchers have discovered a novel method to stimulate the immune system against lung cancer by delivering an immune-stimulating protein via nanoscale containers called vaults. The approach showed potent inhibition of cancer growth in pre-clinical studies and has the potential to be a game-changer in cancer immunotherapy.
Researchers discovered that immune cells play a crucial role in the worsening of atopic dermatitis when exposed to food allergens, with implications for prevention and treatment. Additionally, studies identified TIF1-gamma as a tumor suppressor in mouse and human chronic myelomonocytic leukemia.
Researchers found that temsirolimus strongly blocked mTOR-mediated signals and had a cytostatic effect on all mesothelioma cells. The study suggests using mTOR inhibitors as a novel anti-mesothelioma strategy, particularly in combination with chemotherapy.
The American Society for Radiation Oncology (ASTRO) has developed a guideline for palliative thoracic radiation therapy to treat advanced lung cancer. The guideline recommends various regimens of thoracic external beam radiation therapy as effective for symptom palliation, but not endobronchial brachytherapy or concurrent chemotherapy.
The National Institutes of Health has funded a study to develop an inhaled lung cancer treatment using the drug 5-azacytidine. Researchers at Albert Einstein College of Medicine aim to target premalignant lung cancer by reactivating genes that suppress tumors.
The number of AIDS-defining cancers decreased, while non-AIDS-defining cancers increased significantly between 1991-2005. Lung cancer emerged as the most common malignancy in people with HIV but not AIDS.
A Wayne State University study found that soy isoflavones can sensitize cancer cells to radiation while protecting normal tissue. The study demonstrated that soy isoflavones can block DNA repair mechanisms in cancer cells, leading to increased killing of lung cancer cells by radiation
Researchers at MIT have identified a genetic change that helps lung tumors metastasize, with reduced NKX2-1 activity associated with higher death rates for lung-cancer patients. Understanding this gene's role may help scientists develop drugs to counteract its loss.
A recent study published by the American Association for Cancer Research found that nicotine at doses similar to those found in most nicotine replacement therapies did not increase lung cancer tumor incidence, frequency or size. The researchers concluded that nicotine replacement therapy is probably a safe option.
Researchers found significantly higher rates of HPV antibodies in people with lung cancer compared to those without the disease. High-risk types of HPV were particularly prevalent, suggesting a potential link between HPV infection and lung cancer development.
A recent study presents a promising serum test that can identify lung cancer in people who have never smoked. The test uses a panel of biomarkers to analyze blood samples and has shown high sensitivity and specificity in distinguishing lung cancer from non-cancerous conditions.
Researchers at UT MD Anderson Cancer Center developed two sets of gene expression profiles that predict response to erlotinib treatment for patients with no guiding indicators. The biomarkers, which cover 88% of patients without EGFR mutations, may have a broad impact on identifying patients who benefit from the drug.
Researchers have identified a biomarker for measuring the success of lung cancer chemoprevention, using abnormal cell development (endobronchial dysplasia). The study found that measurements of endobronchial dysplasia can predict how well a chemoprevention agent is working in former smokers.
A recent study published in the Journal of Thoracic Oncology found that soy isoflavones can sensitize cancer cells to radiation, increasing killing efficiency while protecting normal lung tissue from damage. Researchers used a soy mixture consisting of genistein, daidzein and glycitein to demonstrate this effect.
The new TNM 7 lung cancer staging system better predicts local or regional recurrence after surgery, according to a study published in the Journal of Thoracic Oncology. The updated system improved accuracy for predicting disease recurrence among patients with non-small cell lung cancer.
A new therapeutic target for lung cancer has been identified by researchers at Seoul National University. The variant of the protein AIMP2 is highly expressed in lung cancer cells and has been shown to compromise the tumor-suppressing activity of AIMP2, suggesting its potential as a new treatment option.
The annual report to the nation on cancer trends finds a slight decline in brain tumor incidence rates, with a notable increase in non-malignant tumors among adults. Non-malignant tumors were found to be twice as common as malignant tumors in this age group.